Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells.

Nature communications - 25 May 2021

Michalon Aubin, Hagenbuch Andreas, Huy Christian, Varela Evita, Combaluzier Benoit, Damy Thibaud, Suhr Ole B, Saraiva Maria J, Hock Christoph, Nitsch Roger M, Jan Grimm

Abstract excerpt

Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart failure and death. It is characterized by the deposition of extracellular ATTR fibrils in the myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate into restored cardiac function and improved patient survival. For this purpose, we developed the selective anti-ATTR antibody NI301A, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Cardiomyopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase I as Topic

Share to Myocardium

Share to Phagocytosis

Share to Prealbumin

Share to Protein Aggregates

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 34035264
DOI: 10.1038/s41467-021-23274-x
PMCID: PMC8149704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells.PMID 34035264Read ↗

The role of inflammation in a humanized mouse model of transthyretin cardiac amyloidosisSemantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.Semantic proximity Read ↗

AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.Semantic proximity Read ↗

Autoimmune cardiac-specific T cell responses in dilated cardiomyopathy.Semantic proximity Read ↗

Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.Semantic proximity Read ↗

Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated AmyloidosisSemantic proximity Read ↗

Novel drugs targeting transthyretin amyloidosis.Semantic proximity Read ↗

Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseasesSemantic proximity Read ↗

Identification of a novel cardiac epitope triggering T-cell responses in patients with myocardial infarctionSemantic proximity Read ↗

AUTOTAC-mediated targeted degradation of transthyretin aggregates ameliorates hereditary transthyretin amyloidosisSemantic proximity Read ↗

Autoantibody:Autoantigen Competitor Decoys: Application to Cardiac Phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.